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An effective vaccine against the Plasmodium parasite is likely to require the induction
of robust antibody and T cell responses. Chimeric virus-like particles are an effective
vaccine platform for induction of antibody responses, but their capacity to induce
robust cellular responses and cell-mediated protection against pathogen challenge has
not been established. To evaluate this, we produced chimeric constructs using the
murine polyomavirus structural protein with surface-exposed CD8+ or CD4+ T cell or
B cell repeat epitopes derived from the Plasmodium yoelii circumsporozoite protein, and
assessed immunogenicity and protective capacity in a murine model. Robust CD8+ T
cell responses were induced by immunization with the chimeric CD8+ T cell epitope
virus-like particles, however CD4+ T cell responses were very low. The B cell chimeric
construct induced robust antibody responses but there was no apparent synergy when
T cell and B cell constructs were administered as a pool. A heterologous prime/boost
regimen using plasmid DNA priming followed by a VLP boost was more effective than
homologous VLP immunization for cellular immunity and protection. These data show
that chimeric murine polyomavirus virus-like particles are a good platform for induction
of CD8+ T cell responses as well as antibody responses.
Keywords: malaria, vaccine, circumsporozoite protein, virus-like particle, murine polyomavirus, cellular immunity,
T cell responses, Plasmodium yoelii
INTRODUCTION
Although annual malaria related mortality rates have decreased by approximately 25% since
2010, improvements in morbidity and mortality have stabilized in recent years (World Malaria
Report, 2017) and rebounds have been reported in some countries (Alonso et al., 2011). This
is despite an annual financial investment of approximately US$2.7 billion, which includes
malarial preventative measures such as residual spraying, insecticide-treated mosquito nets
and preventative therapies (World Malaria Report, 2017). An effective vaccine is considered
by many to be an essential tool for malaria disease control and eradication (Alonso et al.,
2011). The ideal vaccine would target the pre-erythrocytic stage to induce sterile infection-
blocking immunity which either prevents sporozoite invasion of the hepatocyte and/or
halts the development of the parasite at the liver-stage; this would stop the development
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of clinical symptoms of malaria whichmanifest during the blood-
stage, as well as the transmission of malaria which occurs during
the sexual stage. A partially effective vaccine which reduced liver-
stage parasite burden and thus lowered blood-stage parasitemia
to potentially below a threshold associated with clinical disease
would, however, also be a useful tool.
Recently, GlaxoSmithKline achieved a significant milestone
with MosquirixTM (also known as RTS,S) by receiving a positive
scientific opinion from the European Medicines Agency as the
first malaria vaccine for the immunization of children aged 6
weeks to 17 months. This sub-unit virus-like particle (VLP)
based vaccine targets the P. falciparum circumsporozoite protein
(PfCSP) by combining a protein which includes multiple PfCSP
B cell repeats and T cell epitopes fused with recombinant
hepatitis B surface antigen (RTS), and recombinant wild-type
hepatitis B surface antigen (S) (Gordon et al., 1995). These
recombinant proteins combine to form stable VLPs, which are
co-administered with the AS01 adjuvant (Agnandji et al., 2012).
Disappointingly, clinical studies have shown that although RTS,S
provided some protection in the first year after vaccination, this
efficacy was very low and waned quickly (Tinto et al., 2015;
Olotu et al., 2016) with negative efficacy and a rebound in later
years demonstrated in a long-term follow-up study where RTS,S
immunized 5–17 month children were more likely to be infected
5 years following vaccination (Olotu et al., 2016). These data
emphasize the urgent need to identify new vaccine targets and
vaccine delivery platforms that enhance immunogenicity and
provide durable protection.
The CSP remains the most advanced subunit vaccine
candidate, as a target for neutralizing antibodies prior to liver
infection (Charoenvit et al., 1991; Mishra et al., 2012) and for
T cell responses whilst in the hepatocyte (Grillot et al., 1990;
Weiss et al., 1990, 1992; Franke et al., 1997, 2000). The induction
of T cell or antibody mediated protection against sporozoite
challenge has been demonstrated in murine and non-human
primate models as well as humans by various vaccine platforms
based on the CSP (Sedegah et al., 1994;Walsh et al., 2006;Mettens
et al., 2008; Tewari et al., 2010; Tamminga et al., 2011; Noe
et al., 2014; Janitzek et al., 2016; Collins et al., 2017; Yoshida
et al., 2018). Thus, the CSP is widely considered the antigen of
choice for evaluating novel vaccine delivery platforms targeting
the pre-erythrocytic stage of the parasite life cycle.
Whilst antibody responses generated by chimeric VLP
immunizations using various VLP platforms with antigens
from various pathogens in clinical studies are well-documented
(reviewed in Kushnir et al., 2012), little research has been
done to evaluate their efficacy at generating cellular responses.
Chimeric VLPs using hamster and simian virus 40 polyomavirus
structural proteins have shown antigen-specific cytotoxic T
lymphocyte (CTL) responses with viral epitopes (Mazeike et al.,
2012; Kawano et al., 2014), and a murine polyomavirus VLP
with large HER-21−683 oncogene insert mouse study showed
rejection and inhibition of antigen expressing tumor cells in vivo
(Tegerstedt et al., 2005). Furthermore, both HPV16 L1 VLPs
and their subunit component capsomeres are potent inducers of
CTL responses capable of tumor regression without adjuvants
(Ohlschläger et al., 2003).
In this study, we produced chimeric VLPs using the murine
polyomavirus (MuPyV) (Salunke et al., 1986) by genomic
insertion of either Plasmodium yoelii CSP CD8+
(280−288)
(Weiss
et al., 1992) or CD4+
(59−79)
(Grillot et al., 1990) T cell epitopes,
or the B cell repeat epitope(QGPGAPx2) into a surface-exposed
region of the VP1 structural protein (Middelberg et al., 2011).We
selected the MuPyV-VP1 platform which has been extensively
developed by our group, and can be produced in bacterial
expression systems which can be purified at gram per liter levels
(Liew et al., 2010). The proteins form pentameric capsomeres
(Salunke et al., 1986) which can be chemically induced in vitro
to self-assemble into VLPs (Chuan et al., 2008a; Middelberg
et al., 2011; Rivera-Hernandez et al., 2013). We comprehensively
evaluated antibody and T cell responses as well as protection from
Plasmodium yoelii 17XNL sporozoite challenge using chimeric
PyCSP surface exposed on murine polyomavirus VLP constructs
delivered separately or pooled.
Consistent with previous results with the murine
polyomavirus VLPs (Anggraeni et al., 2013; Rivera-Hernandez
et al., 2013; Wibowo et al., 2014; Seth et al., 2016; Tekewe et al.,
2017), the Plasmodium B cell VLP was a strong inducer of
antigen-specific antibody responses. Additionally, we showed
that the VLP platform was capable of inducing robust VLP-
induced CD8+ T cell responses. However, the VLPs did not
stimulate a good CD4+ T cell response, and there was no
apparent help provided by the CD4 VLP to the VLP-induced
CD8+ T cell responses nor to the induced antibody titers. The
VLP-induced CD8+ T cell responses were however enhanced
using a heterologous DNA prime-boost regimen.
MATERIALS AND METHODS
Plasmid Construction
The plasmid pGEX-4T-1 (GE Healthcare Biosciences, UK)
containing the murine polyomavirus VP1 sequence (M34958)
was provided by Professor Robert Garcea (University of
Colorado, USA). The VP1 sequence was modified by inserting
an AfeI restriction enzyme site flanked with Glycine4-Serine
linker sequences at position 293 and designated pGEX-VP1-
S4-G4S (Middelberg et al., 2011). This allows for antigens to
be inserted into a surface-exposed region of the VP1 protein
with the linker sequences added to reduce structural interference
from the insert on VLP formation. Codon optimized sequences
representing defined PyCSP CD8+ (280−288) (Weiss et al., 1992)
and CD4+ (59−79) (Grillot et al., 1990) T cell epitopes and
the B cell repeat epitope (QGPGAPx2) (Charoenvit et al., 1991)
were separately inserted into the AfeI site in pGEX-VP1-S4-
G4S using standard molecular biology techniques to generate
chimeric CD8+ or CD4+ T cell or B cell VLP constructs. All
constructs were confirmed by Sanger sequencing.
Protein Expression, Purification, and VLP
Assembly
Wild-type pGEX-VP1-S4-G4S, or the chimeric CD8+, CD4+, or
B cell constructs were individually transformed into chemically
competent E. coli Rosetta DE3 pLysS bacteria (Novagen, CA,
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USA). The GST-tagged VP1 proteins were expressed and purified
as previously described (Chuan et al., 2008a; Middelberg et al.,
2011). Briefly, bacteria inoculated Terrific Broth was incubated
at 37◦C and 180 RPM until the OD600 reached approximately
0.5, after which the culture was cooled to 26◦C and induced by
adding 0.2mM Isopropyl β-D-1-thiogalactopyranoside (IPTG)
and incubated overnight at 26◦C and 180 RPM. The cultures
were centrifuged and pellets lysed by sonication then filtered
lysate was passed through a GSTrap HP affinity column (GE
Healthcare, UK) and the purified protein was cleaved from the
GST tag using thrombin (GE Healthcare, UK) and polished
using a Superdex 200 10/300 GL column (GE Healthcare, UK).
Endotoxin levels were reduced (<5 EU/ml) using Vivapure Q
maxi H ion exchange columns (Sartorius Stedim, Germany)
and confirmed with an Endosafe PTS reader (Charles River
Laboratory, USA) as previously described (Middelberg et al.,
2011). VP1 capsomeres were assembled into VLPs by dialysis
against an assembly buffer then against PBS (Chuan et al.,
2008a; Liew et al., 2010; Middelberg et al., 2011). The resultant
VLPs were analyzed by asymmetric flow field-flow fractionation
coupled to multi angle light scattering (AF4-MALS) using an
Eclipse 2 AFFFF system coupled with a Dawn EOS MALS
system (Wyatt Technology Corporation, Santa Barbara, USA),
and transmission electron microscopy (TEM) using a JEOL 1010
(JEOL Ltd., Tokyo, Japan) to assess size distribution as previously
described (Chuan et al., 2008b; Lipin et al., 2008).
Immunization of Mice
All animal experiments were approved by the QIMR Berghofer
Animal Ethics Committee and were conducted in accordance
with the Australian Code of Practice for the Care and Use
of Animals for Scientific Purposes (2004). BALB/c mice (n
= 10/group) aged 7–8 weeks (Animal Resources Center, WA,
Australia) were immunized with the chimeric VLP constructs
three times at 3-week intervals by subcutaneous injection at
the base of the tail. VLPs were administered at two doses,
10 or 30 µg in independent experiments, and individually
or pooled. VLPs were administered without adjuvant as this
platform is considered self-adjuvating (Chackerian et al., 2002;
Stanley, 2006). Synthetic peptides corresponding to the epitopes
presented by the chimeric VLP co-administered with 50 µg of
high molecular weight poly (I:C) adjuvant (Invivogen, USA)
were included as comparator groups in each experiment. In
heterologous prime-boost regimens, mice received two doses
of 100 µg of PyCSP plasmid DNA (pVR2516, Vical Inc, CA,
USA) at 3-week intervals by intramuscular injection into the
tibialis anterior muscle, followed by a booster dose of pooled
VLP or synthetic peptide in poly(I:C) adjuvant as previously
described. In the second experiment, one group received
three homologous immunizations with PyCSP plasmid DNA
at 100 µg per dose. Control groups included wild-type VLPs,
ovalbumin CD8+257−264 and CD4
+
323−339 pooled peptides with 50
µg poly(I:C), and PBS only (naïve). Immunized mice were split
into two groups (n= 5/group) to evaluate either immunogenicity
using splenocytes for T cell assays or protective efficacy by
sporozoite challenge (Figure 1).
Sporozoite Challenge and Protection
Two weeks after the final immunization, mice were challenged
with 1,000 cryopreserved P. yoelii 17 XNL sporozoites (Sanaria
Inc., MD, USA) in 200 µl PBS with 2% naive mouse serum
administered intravenously into the tail vein. Livers were
harvested 42 h post-challenge to assess liver-stage parasite
burden as previously described (Schussek et al., 2013). Briefly,
livers were homogenized in 5ml of RLT buffer (Qiagen,
Netherlands) supplemented with 1% β-2-mercaptoethanol
(Sigma-Aldrich), then RNA was extracted using an RNeasy Mini
kit (Qiagen) following the manufacturer’s protocol. Using 2.5
µg of RNA, cDNA was synthesized using a Super Script VILO
reverse-transcriptase cDNA synthesis kit (Life Technologies,
USA) according to manufacturer’s guidelines. Then the P. yoelii
18S rRNA and murine housekeeping gene glyceraldehyde
3-phosphate dehydrogenase (GAPDH) cDNA were quantified
using quantitative reverse transcriptase-PCR (qRT-PCR) using
a Rotor-gene 3000 (Corbett Research, Mortlake, Australia) with
acquisition on the FAM channel. For Py18S cDNA quantification,
a Taqman Fast Advanced master mix (Applied Biosystems,
Australia) with a custom made Taqman probe [250 nm]
(6FAM-CTGGCCCTTTGAGAGCCCACTGATT-BHQ-1) and
primers [1 um] (5′′- CTTGGCTCCGCCTCGATAT and 3′′-
TCAAAGTAACGAGAGCCCAATG) (Applied Biosystems). A
GAPDH kit (Applied Biosystems) combined with platinum Taq
polymerase, PCR buffers (Invitrogen) was used for GAPDH
quantification. The data are presented as a ratio of copies of
Py18S rRNA per 105 copies of GAPDH.
Splenocyte Harvesting and Stimulation for
T Cell Assays
Ten days after the final immunization, spleens were removed and
single cell suspensions were generated by mechanical disruption
followed by red blood cell lysis. Splenocytes were then co-
incubated with gamma irradiated (16,666 cGy) mouse B cell
lymphoma A20 cells (ATCC TIB-208) which were transfected,
peptide stimulated, or untreated. Transfections with PyCSP
encoded plasmid DNA pVR2516 (Vical, USA) or empty vector
pVR1020 (Vical, USA) plasmid DNA was achieved the AMAXA
Nucleofector system (Lonza, Switzerland) using Kit V and
program C-25 with 5 x 106 A20 cells per cuvette, following
the manufacturer’s protocol. Peptide stimulation used either
PyCSP CD8+ (280−288) or CD4
+
(59−79) T cell epitope synthesized
peptides, or these peptides combined with the B cell repeat
epitope (QGPGAPQGPGAP) peptide at 10µg/ml. For this assay,
cells were incubated in KD-MEMmedia comprised of Dulbecco’s
Modified Eagle’s Medium (SAFC Global, USA) supplemented
with folic acid (136 nM), L-asparagine (32mM), L-arginine
(67mM), sodium bicarbonate (24mM), HEPES (10mM), β-2-
mercaptoethanol (5 nM), L-glutamine (1.5mM), penicillin (100
Units/L), streptomycin (100mg/L) and 10% fetal calf serum. Each
well-contained 5 x 105 splenocytes and 1.5× 105 A20 cells in 200
µl of media. Background responses were removed by subtracting
transfected pVR1020 wells from pVR2516 wells, and untreated
A20 wells from peptide-pulse wells for ELISpot, cytometric bead
array (CBA) and intracellular cytokine staining (ICS) assays.
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FIGURE 1 | Schematic of experimental design. In each experiment, mice (n = 10/group) were immunized three times at a 3-week interval. Plasmid DNA injections
were intramuscular into the tibialis anterior whilst VLP immunizations were subcutaneous on the back near the base of the tail. Blood samples were collected 14 days
after doses 1 and 2 and then 5 days after the final dose to assess antibody responses. Half of the mice were euthanized at 10 days after the final dose and
splenocytes used for immunogenicity assays. The other half were challenged 2 weeks after the final dose by injecting 1,000 P. yoelii sporozoites into a tail vein, and
livers removed 42 h later to assess parasite load by qRT-PCR. In one experiment, the VLP doses were 30 µg for individual VLPs or 10 µg of each in the pooled VLP
group. In another experiment, the pooled VLP dose was increased to 30 µg of each VLP and a DNA-only control was included.
IFN-γ ELISpot Assay
IFN-γ ELISpot assays were conducted as previously described
(Schussek et al., 2017). Briefly, MSIPS4510 multiscreen ELISpot
plate (Merck Millipore, Germany) well were pre-coated
with 100µg/ml anti-mouse IFN-γ (BD Biosciences, USA)
then blocked with KD-MEM supplemented with 10% FCS.
Quadruplicate wells were used for each stimulation. Plates
were incubated for 40 h at 37◦C and 5% CO2. After plate
washing, IFN-γ secreting cells were stained with 2µg/ml
biotinylated anti-mouse IFN-γ (BD Biosciences, USA) followed
by 1µg/ml streptavidin-HRP (BD Biosciences, USA). The
assay was developed using AEC substrate (BD Biosciences,
USA), and spots counted using the AID ELISpot reader system
(Autoimmun Diagnostika GmbH, Germany).
Cytometric Bead Array
Splenocyte/A20 cultures were incubated at 37◦C and 5% CO2
for 72 h. Culture supernatant was collected and secreted IFN-
γ, TNF, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, and IL-
13 cytokines assayed using the mouse cytometric bead array
flex kit (BD Biosciences, USA) following the manufacturer’s
protocol. Samples were analyzed using a FACSArray instrument
(BD Biosciences, USA) using the CBA array software (BD
Biosciences, USA).
Intracellular Cytokine Staining
To detect monofunctional or polyfunctional T cell responses,
splenocyte/A20 cultures were incubated with 0.1% Golgi Plug
(BD Biosciences, USA) for 6 h at 37◦C and 5% CO2. Cells
were stained with anti-CD8+ (53-6.7) and anti-CD4+ (RM4.5)
antibodies before being fixed with 1% paraformaldehyde. Cells
were then stained with anti-IFN-γ (XMG1.2), anti-IL-2 (JES6-
5H4), and anti-TNF-α (MP6-XT22) diluted in permwash
buffer (BD Biosciences, USA). All antibodies were purchased
from Biolegend. Flow cytometric analysis was performed on
a Fortessa 4 (BD Biosciences, USA). Post-acquisition data
analysis was performed using FlowJo software version 10
(Treestar, USA).
ELISA
Antigen-specific antibody responses were detected by ELISA
using the PyCSP B cell repeat peptide linked to a polystyrene
binding tag (Kumada et al., 2010) with a glycine4 spacer
(Kogot et al., 2012) (PST-B cell, RIIIRRIRGGGG-QGPGAPx3)
(Mimotopes, Australia). The PST-tag with a glycine spacer
was incorporated to enhance attachment of the peptide to the
plate and expose the B cell repeat for antibody recognition.
Nunc maxisorp plates (Thermo Fisher Scientific, USA) were
coated overnight with the PST-B cell peptide (5µg/ml) in a
carbonate coating buffer, then blocked with PBS containing
2% BSA. Triplicate wells of sera from mice were titrated by
2-fold dilutions in PBS-BSA 0.1%, and then incubated with
biotinylated donkey α-mouse IgG (Jackson ImmunoResearch
Laboratories, USA) diluted in PBS-BSA 0.1%, followed by
an incubation with streptavidin-HRP (BD Biosciences, USA)
diluted 1:1,000 in PBS-BSA 0.1 and 0.2% Tween20. Plates
were developed with tetramethylbenzidine (TMB) and stopped
using TMB stop reagent (Sigma Aldrich, USA). Absorbance
was measured at 450 nm using a VersaMax microplate reader
(Molecular Devices, USA). Positive results were recorded if
OD450 values were> 3 standard deviations above the mean blank
(no serum) values.
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Statistical Analysis
Statistical analysis was performed using GraphPad Prism version
6.0 (GraphPad, CA, USA). Logarithmic transformed data
of groups were compared by one-way analysis of variance
(ANOVA) and Bonferroni’s multiple comparison test. Statistical
significance is displayed as ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001,
and ∗∗∗∗p < 0.0001.
RESULTS
VLP Construction
In-frame genomic insertion of antigen-derived epitopes into the
MuPyV-VP1 protein was confirmed by sequencing. After the
VLPs were assembled in vitro, analysis using AF4-MALS showed
only small amounts of protein aggregation and TEM images
confirmed that the chimeras had a similar morphology to wild-
type VLPs (Figure 2). The mean radius of each of the chimeric
VLPs was similar to that of the wild type VLPs [Wild type- 21.00
± 1.27 nm; CD8 VLPs- 20.51 ± 0.67 nm; CD4 VLPs- 21.07 ±
0.61 nm; B cell VLPs- 20.85± 0.67 nm (mean radius± SD)].
VLP-Induced T Cell Immune Responses
Mice were immunized with chimeric CD8 or CD4 VLPs to assess
their capacity independently to induce CD8+ or CD4+ T cell
responses, and to evaluate if pooling of the VLPs would result in
an additive or synergistic response. Pooled VLPs were evaluated
in independent experiments at 10 µg per dose and at 30 µg per
dose to dose-match the independent VLPs (Figure 1).
IFN-γ responses detected by ELISpot showed that
homologous immunization with the CD8 VLP induced
significant IFN-γ spot forming cells (SFCs) when stimulated
with pooled peptide or PyCSP transfected A20 cells (p <
0.001) (Figures 3A, 4A). The magnitude of VLP-induced
CD8+ T cell response was similar to that induced by CD8
peptide immunization when stimulated by peptide (but not
transfected A20 cells). In contrast, the CD4 VLP failed to induce
a significant IFN-γ response (Figures 3A, 4A); robust responses
against peptide (p < 0.0001) and transfected stimulation (p <
0.001) were observed in mice immunized in parallel with CD4
peptides in adjuvant (Figure 3A) and similarly in the subsequent
experiment (Figure 4A).
Immunization with pooled CD8 plus CD4 VLPs resulted in a
similar IFN-γ profile to that induced by the individual VLPs, with
a robust response to the CD8 peptide and negligible response to
the CD4 peptide (Figure 4A).
Heterologous prime-boost immunization with DNA
prime/VLP boost induced a stronger response than homologous
VLP immunization (Figures 3A–C). This was attributed to
the plasmid DNA prime with the homologous DNA regimen
inducing the most robust response (Figures 4A–C). The
reduction in responses between the DNA only and DNA
prime/VLP boost could be due to an inhibition caused by
VLPs, but more likely that the third dose of DNA was more
immunogenic than the VLPs.
The profile of IFN-γ responses detected with both CBA and
ICS readouts was similar to that shown by ELIspot for the CD8
and CD4 VLPs (Figures 3A–C, 4A–C). Robust IFN-γ responses
FIGURE 2 | Structural analysis of in vitro assembled chimeric murine
polyomavirus virus-like particles. Wild and chimeric MuPyVP1-G4S proteins
were expressed in E. coli and purified by liquid chromatography. Proteins were
dialyzed against an assembly buffer to form VLPs and then against PBS.
Post-assembly solutions were analyzed to detect the formation of VLPs using
asymmetrical flow field- flow fractionation coupled with multi-angled lights
scattering (AF4-MALS) and transmission electron microscopy of (A) wild-type
VLPs, (B) CD8 VLP chimeras, (C) CD4 VLP chimeras, and (D) B cell VLP
chimeras. UV280 absorbance is displayed relative to peak absorbance (solid
line) for each sample, and particle size is shown as root-square-radius (open
circles). Scale bar is 100 nm.
induced by the CD8 VLP were similar to that induced by peptide
in adjuvant. Negligible CD4+ T cell responses were induced
by CD4 VLP immunizations, as opposed to the robust CD4+
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FIGURE 3 | Cellular immune responses induced by individual (30 µg) or pooled (10 µg each) chimeric VLP immunizations. BALB/c mice (n = 5/group) were
immunized with a prime/boost regimen using two i.m., priming immunizations with PyCSP plasmid DNA (100 µg) followed by a single s.c. boost using either pooled
PyCSP VLPs (10 µg each) or pooled PyCSP peptides (30 µg each) with poly(I:C); or with three homologous s.c doses of pooled PyCSP VLPs (10 ug each) or
individual PyCSP VLPs (30 ug); or pooled or individual PyCSP peptides (30 µg each) with poly(I:C); wild type VLPs (30 µg); pooled ovalbumin peptides (30 µg each)
with poly(I:C); or PBS only. Ten days after the final boost, splenocytes (5 × 105/well) were cultured with irradiated A20 cells pulsed with pooled PyCSP CD8280−288,
CD459−79, or B cell peptides (1.5 × 10
5/well), or with irradiated A20 cells transfected with pVR2516 PyCSP plasmid DNA (5 × 104/well), for assessment of T cell
specific immune responses. (A) IFN-γ ELISpot was used to determine IFN-γ spot forming cells/million splenocytes following 40 h incubation with pooled CD8280−288
plus CD459−79 peptides (left) or DNA transfected A20 cells (right). (B) ICS was used to determine CD8
+ and CD4+ T cell, IFN-γ, IL-2, and TNF cytokine responses
following 18 h stimulation with pooled peptides, with the final 6 h supplemented with GolgiPlug. (C) Cytometric Bead Array (CBA) was used to quantify cytokine
concentrations in 72 h culture supernatant following pooled peptide stimulation. All data are presented as group means + SEM (media only subtracted). Statistical
comparisons are made to the PBS control group, and between homologous VLP and peptide immunization groups using log-transformed data with significance
determined using one-way ANOVA followed by Bonferroni’s post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
T cell responses which were evident following CD4 peptide
immunization. This differentiation is likely due to the reduced
actual peptide load in the CD4 VLPs of approximately 0.52 µg.
TNF was induced in mice immunized with the CD4 peptide
individually or in pools (Figures 3C, 4C). TNF was also
significantly induced by DNA immunizations in response to
pooled peptide (p < 0.01) and CD4 peptide stimulation (p <
0.0001). No VLP immunizations resulted in significant TNF or
IL-2 production from stimulated splenocytes. Our CBA assessed
a range of cytokines specifically: IFN-γ, L-1β, IL-2, IL-4, IL-5, IL-
6, IL-10, IL-12p70, IL-13 and TNF. However, with the exception
of IFN-γ and TNF, we only detected a very low level of cytokines
induced by our VLP immunizations (data not shown).
VLP-Induced Antibody Responses
The B cell VLPwas predicted to induce strong antibody responses
since it comprised the dominant PyCSP B cell linear epitope
exposed on the surface of the VLP in a repetitive array. Responses
to the B cell VLPwere assessed in parallel individually as well as in
a pool with the CD8 and CD4 VLPs since it was anticipated that
the inclusion of the CD4 VLP would enhance the epitope-specific
antibody titer.
Robust anti-PyCSP B cell peptide IgG responses were induced
by all groups containing the B cell VLP (p < 0.0001 relative to
naive) (Figure 5). In the homologous VLP immunizations, there
were no significant differences between any groups indicating
no additive effect by including the CD4 VLP. VLP-induced
antibody responses were significantly higher than homologous
DNA immunizations (p< 0.0001). In the DNA prime/VLP boost
regimen, the response induced by the 10 µg/construct boost
was significant higher as compared to the 30 µg/construct boost
(p < 0.01); conversely in the homologous VLP only groups, the
30 µg per dose group higher than the 10 µg per dose, although
not significantly different.
Protection From Sporozoite Challenge
To evaluate the protective efficacy of chimeric VLPs, VLP-
immunized mice (n = 5/group) were challenged with 1,000 P.
yoelii 17XNL sporozoites. In the first experiment, 40% (2/5) mice
immunized with DNA prime / VLP boost had no parasite RNA
detected in their liver and there was a 38% reduction in liver-stage
parasite burden relative to the PBS control group overall in the
group; these differences were not significant given the relatively
small group sizes. When the experiment was repeated using
the higher dose pooled VLPs (30 µg/construct), a significant
reduction in parasite burden was noted in mice immunized with
the heterologous DNA prime / VLP pooled VLP regimen (p <
0.01) (Figure 6). This equates to a mean 72% reduction in the
liver parasite burden relative to the PBS immunized group. In the
pooled VLP immunizedmice, there was a mean 57% reduction in
liver-stage parasite burden relative to the PBS control, although
this did not reach statistical significance.
DISCUSSION
Development of an efficacious malaria vaccine has been
challenging, with even the most advanced candidate
MosquirixTM showing very poor efficacy despite very
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FIGURE 4 | Cellular immune responses induced by individual (30 µg) or pooled (30 µg each) chimeric VLP immunizations. BALB/c mice (n = 5/group) received three
immunizations at 3 week intervals with three homologous i.m., PyCSP plasmid DNA (100 µg) immunizations or a prime/boost regimen using two i.m., priming
immunizations with PyCSP plasmid DNA (100 µg) followed by a single s.c. boost using either pooled PyCSP VLPs (30 µg each) or pooled PyCSP peptides (30 µg
each) with poly(I:C); or three homologous s.c doses of pooled or individual PyCSP VLPs (30 µg each) or PyCSP peptides (30 µg each) with poly(I:C); wild type VLPs
(30 µg); pooled ovalbumin peptides (30 µg each) with poly(I:C); or PBS only. (A) IFN-γ ELIspot, (B) ICS, and (C) CBA responses were assayed as described in the
legend to Figure 3, using individual CD8 peptides or CD4 peptides, pooled peptides, or DNA-transfected A20 cells. All data sets are presented as group means +
SEM (media only subtracted). Statistical comparisons are made to the PBS control group, and between homologous VLP and peptide immunization groups using
log-transformed data with significance determined using one-way ANOVA followed by Bonferroni’s post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, and
****p < 0.0001 (nt, not tested).
extensive refinement during preclinical development and
early stage clinical testing (Tinto et al., 2015; Olotu et al.,
2016). MosquirixTM is a chimeric VLP construct expressing
the central repeat region plus the entire C-terminal flanking
region (amino acids 207–395) of the P. falciparum CSP fused
to the hepatitis B virus surface antigen, HBsAg. Protection
has been associated with antibodies or CD4+ T cell responses,
but this vaccine fails to induce CD8+ T cell responses which
are thought to be required for protection against intracellular
pathogens such as the Plasmodium spp. parasite (Seder and
Hill, 2000). Various Plasmodium targets have been evaluated
using a range of subunit vaccine delivery platforms including
recombinant protein, recombinant viruses, synthetic peptides,
plasmid DNA, nanoparticles, and VLPs [reviewed in Draper et al.
(2015)]. However, none of these platforms have induced robust
CD8+ and CD4+ T cell responses as well as antibody responses
sufficient for protection against malaria. In other disease models,
VLP vaccines show potential for induction of broad antibody
and cellular immune responses.
Protection directed against the pre-erythrocytic stage of
the Plasmodium lifecycle following sporozoite challenge can
be achieved primarily by antibody responses which inhibit
sporozoite infection of the hepatocyte (Majarian et al., 1984;
Charoenvit et al., 1991) or CD8+ T cell responses which act
directly or indirectly upon the liver-stage parasite (Weiss et al.,
1988, 1990, 1992; Doolan and Hoffman, 2000); moreover, there is
evidence that induction of CD4+ T cell responses is required for
optimal efficacy (Weiss et al., 1993). There is increasing interest
in immunization regimens which induce liver-resident memory
T cells as the parasite-infected liver is considered the primary site
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FIGURE 5 | Anti-PyCSP B cell peptide IgG responses induced by
immunization with individual or pooled VLP immunizations. In separate series
of experiments, mice (n = 10/group) were immunized with individual VLPs (30
µg/dose) or pooled VLPs (either 10 µg/construct or 30 µg/construct), as
described in the legends to Figures 3, 4. Sera collected 5 days following the
final immunization were batch analyzed by ELISA to determine the anti-B cell
peptide-specific IgG endpoint titer. Data is presented as mean endpoint titer +
SEM. Statistical comparisons between immunization groups used
log-transformed data with significance determined using one-way ANOVA
followed by Bonferroni’s post-hoc test. **p < 0.01, ***p < 0.001, and
****p < 0.0001.
for protective T cell mediated immune responses which act to
reduce liver-stage parasite burden (Fernandez-Ruiz et al., 2016;
Gola et al., 2018; Olsen et al., 2018). It is possible that immune
responses measured in the periphery or in splenocytes may not
accurately reflect the vaccine-induced responses in the liver,
so future studies should consider evaluation of liver-resident
memory T cells in addition to the more traditional readouts
from splenocytes.
Many VLP vaccine platforms have been developed, using
structural proteins from various viral species. VLPs based on
the murine polyomavirus are considered a promising VLP
for vaccine development because of their reported humoral
immunogenicity and their ability to be produced reproducibly
with high yields (Chuan et al., 2008a; Liew et al., 2010,
2012; Middelberg et al., 2011; Anggraeni et al., 2013; Rivera-
Hernandez et al., 2013; Wibowo et al., 2014; Seth et al., 2016;
Tekewe et al., 2017). However, their capacity to induce robust
antibody plus CD4+ and CD8+ T cell responses has not been
thoroughly investigated. Accordingly, we evaluated both cellular
and antibody responses using chimeric murine polyomavirus
VLPs incorporating the CSP as a vaccine delivery platform, in the
P. yoeliimurine model.
It is well-established that VLPs are very effective at inducing
antigen-specific antibody responses [reviewed in Grgacic and
Anderson (2006)] likely due to their ability cross-link B cell
surface receptors (Thönes et al., 2008) acting in a T cell
FIGURE 6 | Protective capacity induced by individual or pooled chimeric VLPs
using homologous or heterologous immunization regimens. In two
independent experiments (A) BALB/c mice (n = 5/group) were immunized
with three immunizations at 3-week intervals (as in Figure 3) with a
prime-boost regimen using two i.m. PyCSP plasmid DNA (100 µg) primes
followed by a s.c. boost of either pooled PyCSP VLPs (10 µg each) or pooled
PyCSP peptides (30 µg each); or three homologous s.c. immunizations with
pooled PyCSP VLPs (10 µg each) or pooled PyCSP peptides (30 µg each) in
poly(I:C); or individual PyCSP B cell, CD4 or CD8 VLPs (30 µg) or
corresponding peptides (30 µg) with poly(I:C); or wild-type VLPs (30 µg); or
ovalbumin pooled peptides (30 µg each) with poly(I:C); or PBS only. (B)
BALB/c mice (n = 5/group) were immunized with three immunizations at
3-week intervals (as in Figure 4) with three i.m immunizations of PyCSP
plasmid DNA (100 µg); a prime/boost regimen or homologous regimens as
above with dosing modifications to pooled PyCSP VLPs increasing to 30 µg
per VLP. In both experiments, mice were challenged 2 weeks after the final
immunization by i.v., injection of 1,000 P. yoelii 17XNL cryopreserved
sporozoites. Parasite burden was assessed by qRT-PCR analysis of Py18s
rRNA extracted from livers harvested 42 h post-challenge and calculated as a
ratio to the GAPDH housekeeping-gene mRNA. Results for individual mice are
shown, with bars representing the group mean. The dotted line represents the
naïve mouse mean. Log-transformed ratio data was analyzed using one-way
ANOVA followed by Bonferroni’s post-hoc test. **p < 0.01.
independent manner (Snapper and Mond, 1993; Szomolanyi-
Tsuda and Welsh, 1998). Consistent with that, herein we showed
that our B cell VLP induced high IgG titres against the PyCSP
B cell epitope. There was a significant decrease in antibody
titers in the DNA prime/VLP boost group when the pooled VLP
component was increased from 10 to 30 µg per VLP (Figure 5).
This variation was not seen in the VLP only immunized mice,
but those mice received three VLP doses and the additional doses
may have normalized the responses.
We established that immunizations with either chimeric CD8
VLPs alone, or as pooled with a B cell VLP and CD4T cell VLP
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were able to induce moderate levels of IFN-γ directed against
the CD8+ T cell epitope presented as a synthetic peptide or in
the context of whole antigen transfectant, with both ELISpot
and ICS (Figures 3A,C, 4A,C). This antigen-specific recognition
confirms that the CD8 chimeric VLP presented the incorporated
CD8+ T cell epitope in vivo to naive CD8+ T cells, and that this
presentation was via MHC class I molecules (Heath et al., 2004).
These results are consistent with previous studies reporting that
chimeric VLPs incorporating a single CD8+ T cell epitope from
viral or ovalbumin targets induced CTL activity mediated by
CD8+ T cells (Sedlik et al., 1997; Crisci et al., 2009). It is possible
that our immunizations with pooled VLPs using 30 µg of each
construct failed to protect mice from challenge as the induced
CD8+ T cell response was insufficient to protect (Schmidt et al.,
2008) with amean frequency of 0.59% of CD8+ T cells expressing
IFN-γ (Figure 4B).
We had anticipated that immunizing with a pool of VLPs
which included the CD4T cell peptide might result in an additive
or synergistic response, as noted for immunization with a pool of
the synthetic peptides. However, there was no evidence of any
additive or synergistic effects on CD8+ T cell responses when
VLPs were administered as a pool with the CD4 VLP; this was
likely due to the very low responses induced by the CD4 VLP.
The carrier MuPyV VP1 protein is likely to contain CD4+ T
helper epitopes similar to those in the HBV core protein (Schödel
et al., 1992; Bickert et al., 2007) and may provide carrier-related
T cell help for antibody responses, but those would provide
no antigen-specific help against challenge by the Plasmodium
parasite. Poly (I:C) was selected to adjuvant the synthetic peptides
in vivo because it is a known inducer of type I (Salem et al.,
2005; Qiu and Cui, 2007; Coffman et al., 2010; Schneider-Ohrum
et al., 2011) and II (Tewari et al., 2010; Kastenmüller et al.,
2013) cellular responses. However, VLPs are generally considered
self-adjuvating due to their viral structure (Stanley et al., 2006;
Chackerian, 2007). There are however contradictory reports,
with some reports showing that adjuvants are essential (Storni
et al., 2002), beneficial (Freyschmidt et al., 2004; Ding et al.,
2009) or not necessary (Mazeike et al., 2012; Rivera-Hernandez
et al., 2013; Kawano et al., 2014). In our studies, we elected to
exclude adjuvants so as to better understand the immunogenicity
of our chimeric VLPs.We cannot however rule out the possibility
that administration of the CD4 VLP with poly(I:C) could have
enhanced the VLP-induced T cell response, but other data
generated in our laboratory showed no enhancement of CD4+
T cell when pooled VLPs were co-administered with poly(I:C)
(manuscript in preparation).
In our VLP constructs, each T cell epitope was inserted
into surface-exposed regions of the VP1 protein, since we
predicted that epitopes inserted into this region would be less
likely to interfere with VLP formation. It is possible that this
location may not have been optimal for the induction of cellular
immune responses and that placing the epitopes on terminal
regions may have been beneficial, as reported in one study in
a chimeric calicivirus-like VLP system with ovalbumin CD8
epitopes showing significantly higher IFN-γ responses, target-
specific lysis and protection (Crisci et al., 2009). It is also
possible that the lack of responses to the CD4 epitope may have
been a dose related issue; the CD4 peptide component of the
30 µg VLP dose was approximately 0.52 µg peptide epitope
equivalent, whereas the peptide immunized mice received nearly
60 times the epitope per dose. Our immunogenicity assessments
used lymphocytes taken from spleen and not draining lymph
nodes, but the strong responses detected in splenocytes from the
peptide-immunized mice would be expected to accurately reflect
a response in the draining lymph nodes; if the VLPs induced a
robust CD4+ T cell response then this should also have been
detected in splenocytes.
To evaluate the protective capacity of our chimeric VLPs,
we harvested livers 42 h post- sporozoite challenge, at the late
liver-stage of the P. yoelii lifecycle before parasites were expected
to release into the blood (Baer et al., 2007). This timepoint
maximized the opportunity for VLP-induced protective immune
responses to clear parasite-infected cells. Liver-stage protection
has previously been achieved by adoptively transferring a
CD8+280−288 T cell clone (Weiss et al., 1988), or by passive transfer
of monoclonal antibodies specific to the PyCSP central repeat
(Charoenvit et al., 1991). These protective antigenic epitopes
were incorporated within our VLP chimeras, and generated
epitope-specific CD8+ T cell and antibody responses. In our
study, there was evidence that VLPs could induce protection
against sporozoite challenge since sterile protection was seen
in 2 of 5 mice and there was a reduction in parasite load;
however, this protection was suboptimal. Our immunological
data supports the induction of the type of immune response
required to protect against Plasmodium sporozoite challenge, but
the magnitude of those VLP-induced responses may have been
insufficient to reach a protective threshold (Schmidt et al., 2010).
This is consistent with other studies where protection correlated
with the number of adoptively transferred clonal CD8+280−288 T
cells where 20 × 106 cells were required for sterile protection
(Weiss et al., 1992), or with the number of memory CD8+ T
cells stimulated by immunizations (Schmidt et al., 2008, 2010),
or with the amount of passive transferred monoclonal antibodies
(Charoenvit et al., 1991).
Indeed, we found that more robust antibody and cellular
responses were induced by a prime/boost regimen as compared
with homologous VLPs, and we anticipate that this would be
further enhanced with the inclusion of a second VLP boost.
Overall, our data showed that the MuPyV chimeric VLP
platform is capable of inducing antigen-specific antibody
responses, and established for the first time for this vaccine
platform, their capacity to induce CD8+ T cell immune
responses. Future studies could evaluate alternative epitope
insertion sites within the MuPyV VP1 protein to determine if
other sites enhance cellular immune responses, or the inclusion
of adjuvants in the vaccination regimen. Additional regions of
the target antigens (e.g., repetitive regions targeted by antibody
responses, together with T helper epitopes) could also be
included. Alternative target antigens could be also evaluated
since studies have suggested that multiple antigen targets may
be required for protection from Plasmodium challenge (Doolan
et al., 1996; John et al., 2005; Osier et al., 2008). With
approximately 2,000 active genes, and 816 identified proteins
present during Plasmodium liver-stage of infection (Tarun et al.,
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2008) part of the challenge is to identify the most optimal target
antigens for induction of vaccine-induced protective immunity
(Schussek et al., 2017).
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